Met Life Investment Management, LLC Viracta Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$3.37 - $7.91 $17,082 - $40,095	-5,069 Closed	0 $0
Q3 2021 May 17, 2024	SELL	$7.84 - $12.53 $75,561 - $120,764	-9,638 Reduced 65.53%	5,069 $40,000
Q3 2021 Jun 21, 2023	BUY	$7.84 - $12.53 $39,740 - $63,514	5,069 New	5,069 $40,000
Q3 2021 Mar 22, 2023	SELL	$7.84 - $12.53 $75,561 - $120,764	-9,638 Reduced 65.53%	5,069 $40,000
Q3 2021 Nov 15, 2021	SELL	$7.84 - $12.53 $75,561 - $120,764	-9,638 Reduced 65.53%	5,069 $41,000
Q2 2021 May 17, 2024	BUY	$7.55 - $12.95 $111,037 - $190,455	14,707 New	14,707 $166,000
Q2 2021 Jun 21, 2023	BUY	$7.55 - $12.95 $111,037 - $190,455	14,707 New	14,707 $166,000
Q2 2021 Mar 22, 2023	BUY	$7.55 - $12.95 $111,037 - $190,455	14,707 New	14,707 $166,000
Q2 2021 Aug 16, 2021	BUY	$7.55 - $12.95 $111,037 - $190,455	14,707 New	14,707 $167,000

9.03M

10.9K

400

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $8.64M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.